New Alzheimer's treatment enters human testing
NCT ID NCT06189963
Summary
This early-stage study aims to test the safety and early signs of effectiveness of an investigational drug called SNK01 for people with moderate Alzheimer's disease. It will involve 36 participants who will receive intravenous infusions every three weeks for up to one year. Researchers will primarily monitor for side effects and also look for any changes in memory, thinking skills, and disease-related markers in the blood and spinal fluid.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AdventHealth Research Institute
RECRUITINGOrlando, Florida, 32804, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Behavioral Research Specialists, LLC
RECRUITINGGlendale, California, 91206, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ottawa Memory Clinic
NOT_YET_RECRUITINGOttawa, Ontario, K1Z 1G3, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Syrentis Clinical Research
RECRUITINGSanta Ana, California, 92705, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Valiance Clinical Research
RECRUITINGTarzana, California, 91356, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.